{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T17:25:09Z","timestamp":1769275509303,"version":"3.49.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T00:00:00Z","timestamp":1556064000000},"content-version":"vor","delay-in-days":1939,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World Allergy Organization Journal"],"published-print":{"date-parts":[[2014]]},"DOI":"10.1186\/1939-4551-7-32","type":"journal-article","created":{"date-parts":[[2014,12,4]],"date-time":"2014-12-04T03:03:35Z","timestamp":1417662215000},"page":"32","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"special_numbering":"C","title":["Anti-IL5 therapy for asthma and beyond"],"prefix":"10.1016","volume":"7","author":[{"given":"Manali","family":"Mukherjee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roma","family":"Sehmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parameswaran","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1186\/1939-4551-7-32_bib0005","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaci.2013.05.007","article-title":"What is an \u201ceosinophilic phenotype\u201d of asthma?","volume":"132","author":"Nair","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1186\/1939-4551-7-32_bib0010","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1146\/annurev.immunol.24.021605.090720","article-title":"The Eosinophil","volume":"24","author":"Rothenberg","year":"2006","journal-title":"Annu Rev Immunol"},{"issue":"supplement_1","key":"10.1186\/1939-4551-7-32_bib0015","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1164\/ajrccm.160.supplement_1.14","article-title":"Induced sputum, eosinophilic bronchitis, and chronic obstructive pulmonary disease","volume":"160","author":"Hargreave","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1186\/1939-4551-7-32_bib0020","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/all.12088","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss): state of the art","volume":"68","author":"Vaglio","year":"2013","journal-title":"Allergy"},{"issue":"4","key":"10.1186\/1939-4551-7-32_bib0025","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jaci.2009.11.048","article-title":"A review of treatment with mepolizumab, an anti\u2013IL-5 mAb, in hypereosinophilic syndromes and asthma","volume":"125","author":"Busse","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1186\/1939-4551-7-32_bib0030","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1067\/mai.2000.105712","article-title":"Mechanisms of eosinophil-associated inflammation","volume":"105","author":"Gleich","year":"2000","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1186\/1939-4551-7-32_bib0035","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1084\/jem.183.1.195","article-title":"Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model","volume":"183","author":"Foster","year":"1996","journal-title":"J Exp Med"},{"issue":"15","key":"10.1186\/1939-4551-7-32_bib0040","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJM199010113231505","article-title":"Eosinophilic inflammation in asthma","volume":"323","author":"Bousquet","year":"1990","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1186\/1939-4551-7-32_bib0045","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1164\/ajrccm.157.1.9703027","article-title":"Effect of inhaled interleukin-5 on airway hyperreactivity and eosinophilia in asthmatics","volume":"157","author":"Shi","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1186\/1939-4551-7-32_bib0050","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/MCP.0000000000000007","article-title":"Monoclonal antibodies for the treatment of refractory asthma","volume":"20","author":"Hambly","year":"2014","journal-title":"Curr Opin Pulm Med"},{"issue":"12","key":"10.1186\/1939-4551-7-32_bib0055","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/nrd3792","article-title":"The potential of biologics for the treatment of asthma","volume":"11","author":"Pelaia","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"129","key":"10.1186\/1939-4551-7-32_bib0060","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1183\/09059180.00004013","article-title":"Anti-interleukin-5 therapy in severe asthma","volume":"22","author":"Garcia","year":"2013","journal-title":"Eur Respir Rev"},{"issue":"4","key":"10.1186\/1939-4551-7-32_bib0065","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2222.2010.03484.x","article-title":"Eosinophils in health and disease: the LIAR hypothesis","volume":"40","author":"Lee","year":"2010","journal-title":"Clin Exper Allergy"},{"issue":"7","key":"10.1186\/1939-4551-7-32_bib0070","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/all.12169","article-title":"The consequences of not having eosinophils","volume":"68","author":"Gleich","year":"2013","journal-title":"Allergy"},{"key":"10.1186\/1939-4551-7-32_bib0075","series-title":"Advances in Pharmacology","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-404717-4.00001-9","article-title":"Chapter One - Redefining Approaches to Asthma: Developing Targeted Biologic Therapies","author":"Arron","year":"2013"},{"issue":"9248","key":"10.1186\/1939-4551-7-32_bib0080","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/S0140-6736(00)03496-6","article-title":"Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-respons\u00ecveness, and the late asthmatic response","volume":"356","author":"Leckie","year":"2000","journal-title":"Lancet"},{"issue":"5","key":"10.1186\/1939-4551-7-32_bib0085","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1183\/09031936.03.00027302","article-title":"Monoclonal anti-interleukin\u20125 treatment suppresses eosinophil but not T\u2012cell functions","volume":"21","author":"B\u00fcttner","year":"2003","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1186\/1939-4551-7-32_bib0090","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1164\/rccm.200206-525OC","article-title":"Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma","volume":"167","author":"Kips","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1186\/1939-4551-7-32_bib0095","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1164\/rccm.200208-789OC","article-title":"Eosinophil\u2019s role remains uncertain as anti\u2013interleukin-5 only partially depletes numbers in asthmatic airway","volume":"167","author":"Flood-Page","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1186\/1939-4551-7-32_bib0100","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1164\/rccm.200701-085OC","article-title":"A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma","volume":"176","author":"Flood-Page","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1186\/1939-4551-7-32_bib0105","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia","volume":"360","author":"Nair","year":"2009","journal-title":"New Engl J Med"},{"issue":"10","key":"10.1186\/1939-4551-7-32_bib0110","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"New Engl J Med"},{"issue":"9842","key":"10.1186\/1939-4551-7-32_bib0115","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"issue":"10","key":"10.1186\/1939-4551-7-32_bib0120","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Reslizumab for poorly controlled, eosinophilic asthma","volume":"184","author":"Castro","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1186\/1939-4551-7-32_bib0125","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jaci.2010.04.005","article-title":"Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti\u2013IL-5 receptor \u03b1 antibody, in a phase I study of subjects with mild asthma","volume":"125","author":"Busse","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1186\/1939-4551-7-32_bib0130","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaci.2013.05.020","article-title":"Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia","volume":"132","author":"Laviolette","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1186\/1939-4551-7-32_bib0135","series-title":"B101 Asthma Pathogenesis","article-title":"Benralizumab reduces exacerbations and improves lung function in adults with uncontrolled eosinophilic asthma","author":"Mario","year":"2014"},{"issue":"13","key":"10.1186\/1939-4551-7-32_bib0140","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1186\/1939-4551-7-32_bib0145","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1186\/1939-4551-7-32_bib0150","series-title":"European Respiratory Society Annual Congress","article-title":"A randomized phase 3 study f reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma","author":"Corren","year":"2014"},{"key":"10.1186\/1939-4551-7-32_bib0155","series-title":"European Respiratory Society Annual Congress","article-title":"A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils","author":"Bjermer","year":"2014"},{"issue":"13","key":"10.1186\/1939-4551-7-32_bib0160","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMe1408614","article-title":"Anti-interleukin-5 monoclonal antibody to treat severe eosinophilic asthma","volume":"371","author":"Nair","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1186\/1939-4551-7-32_bib0165","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1034\/j.1398-9995.2003.00110.x","article-title":"Enhanced soluble interleukin-5 receptor alpha expression in nasal polyposis","volume":"58","author":"Gevaert","year":"2003","journal-title":"Allergy"},{"issue":"1","key":"10.1186\/1939-4551-7-32_bib0170","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1517\/14712598.2012.642359","article-title":"Benralizumab \u2013 a humanized mAb to IL-5R\u03b1 with enhanced antibody-dependent cell-mediated cytotoxicity \u2013 a novel approach for the treatment of asthma","volume":"12","author":"Ghazi","year":"2011","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"10.1186\/1939-4551-7-32_bib0175","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ccm.2012.05.003","article-title":"How to diagnose and phenotype asthma","volume":"33","author":"Nair","year":"2012","journal-title":"Clin Chest Med"},{"issue":"9","key":"10.1186\/1939-4551-7-32_bib0180","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1164\/rccm.200708-1251OC","article-title":"Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses","volume":"177","author":"Gauvreau","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1186\/1939-4551-7-32_bib0185","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/cea.12244","article-title":"Safety and efficacy of an oral CCR3 antagonist in patients with asthma and eosinophilic bronchitis: a randomized, placebo-controlled clinical trial","volume":"44","author":"Neighbour","year":"2014","journal-title":"Clin Exper Allergy"},{"issue":"8","key":"10.1186\/1939-4551-7-32_bib0190","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nm.3300","article-title":"Eosinophils in the Spotlight: Eosinophilic airway inflammation in nonallergic asthma","volume":"19","author":"Guy","year":"2013","journal-title":"Nat Med"},{"issue":"6","key":"10.1186\/1939-4551-7-32_bib0195","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/ni.2617","article-title":"TH2, allergy and group 2 innate lymphoid cells","volume":"14","author":"Licona-Limon","year":"2013","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1186\/1939-4551-7-32_bib0200","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jaci.2014.02.015","article-title":"Innate lymphoid cells and asthma","volume":"133","author":"Yu","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1186\/1939-4551-7-32_bib0205","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.coi.2013.02.010","article-title":"Development and function of group 2 innate lymphoid cells","volume":"25","author":"Walker","year":"2013","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"10.1186\/1939-4551-7-32_bib0210","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1084\/jem.20062211","article-title":"Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells","volume":"204","author":"Allakhverdi","year":"2007","journal-title":"J Exp Med"},{"issue":"4","key":"10.1186\/1939-4551-7-32_bib0215","doi-asserted-by":"crossref","first-page":"L847","DOI":"10.1152\/ajplung.00245.2001","article-title":"IL-13 and IL-4 cause eotaxin release in human airway smooth muscle cells: a role for ERK","volume":"282","author":"Moore","year":"2002","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"6","key":"10.1186\/1939-4551-7-32_bib0220","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1165\/ajrcmb.24.6.4351","article-title":"Interleukin-13 upregulates eotaxin expression in airway epithelial cells by a STAT6-dependent mechanism","volume":"24","author":"Matsukura","year":"2001","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"2","key":"10.1186\/1939-4551-7-32_bib0225","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2222.2011.03889.x","article-title":"Interleukin-4 and interleukin-13 prime migrational responses of haemopoietic progenitor cells to stromal cell-derived factor-1\u03b1","volume":"42","author":"Punia","year":"2012","journal-title":"Clin Exp Allergy"},{"key":"10.1186\/1939-4551-7-32_bib0230","unstructured":"Roma S, Kayla M, Anam I, Navneet P, Steven GS: Thymic stromal lymphopoietin (TSLP) and IL-33 prime the migrational responses of eosinophil-lineage committed progenitor cells. In A14 Interleukin-33: A Pivotal Mediator for Crosstalk between Innate and Adaptive Inflammatory Responses in the Lung. American Thoracic Society; 2013:A1005\u2013A1005."},{"key":"10.1186\/1939-4551-7-32_bib0235","doi-asserted-by":"crossref","first-page":"A24","DOI":"10.1186\/1710-1492-7-S2-A24","article-title":"Effects of thymic stromal lymphopoietin on cord blood progenitor cell differentiation and hemopoietic cytokine receptors expression","volume":"7","author":"Hui","year":"2011","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"9171","key":"10.1186\/1939-4551-7-32_bib0240","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(99)01813-9","article-title":"Non-eosinophilic cor ticosteroid unresponsive asthma","volume":"353","author":"Pavord","year":"1999","journal-title":"Lancet"},{"issue":"7","key":"10.1186\/1939-4551-7-32_bib0245","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/j.1365-2222.2009.03246.x","article-title":"Human airway smooth muscle promotes eosinophil differentiation","volume":"39","author":"Fanat","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1186\/1939-4551-7-32_bib0250","series-title":"Allergy Frontiers: Classification and Pathomechanisms","first-page":"421","article-title":"Allergy and the bone marrow: transmigration pathways of hemopoietic progenitor cells from the bone marrow","author":"Sehmi","year":"2009"},{"issue":"3","key":"10.1186\/1939-4551-7-32_bib0255","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1165\/ajrcmb.20.3.3060","article-title":"Immunolocalization of CD34 in nasal polyposis. Effect of topical corticosteroids","volume":"20","author":"Kim","year":"1999","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"3","key":"10.1186\/1939-4551-7-32_bib0260","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.4049\/jimmunol.164.3.1538","article-title":"Evidence for local eosinophil differentiation within allergic nasal mucosa: inhibition with soluble IL-5 receptor","volume":"164","author":"Cameron","year":"2000","journal-title":"J Immunol"},{"issue":"26","key":"10.1186\/1939-4551-7-32_bib0265","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in Persistent Asthma with Elevated Eosinophil Levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1186\/1939-4551-7-32_bib0270","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jaci.2003.10.049","article-title":"Anti\u2013interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes","volume":"113","author":"Garrett","year":"2004","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"10.1186\/1939-4551-7-32_bib0275","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"New Engl J Med"},{"issue":"4","key":"10.1186\/1939-4551-7-32_bib0280","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jaci.2010.06.049","article-title":"Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome","volume":"126","author":"Roufosse","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1186\/1939-4551-7-32_bib0285","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jaci.2010.03.028","article-title":"Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome","volume":"125","author":"Kim","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1186\/1939-4551-7-32_bib0290","doi-asserted-by":"crossref","first-page":"341","DOI":"10.7326\/0003-4819-155-5-201109060-00026","article-title":"Targeting interleukin-5 in refractory and relapsing churg\u2013strauss syndrome","volume":"155","author":"Moosig","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1186\/1939-4551-7-32_bib0295","doi-asserted-by":"crossref","unstructured":"Brightling CE, Bleecker ER, Panettieri RA, Bafadhel M, She D, Ward CK, Xu X, Birrell C, van der Merwe R: Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med 2014, Sept 5 2014, published online.","DOI":"10.1016\/S2213-2600(14)70187-0"},{"issue":"1","key":"10.1186\/1939-4551-7-32_bib0300","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jaci.2009.10.014","article-title":"Sustained response to mepolizumab in refractory Churg-Strauss syndrome","volume":"125","author":"Kahn","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1186\/1939-4551-7-32_bib0305","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1128\/CMR.00025-12","article-title":"Eosinophilic pneumonias","volume":"25","author":"Akuthota","year":"2012","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"10.1186\/1939-4551-7-32_bib0310","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.pharmthera.2013.07.001","article-title":"Targeted therapy of bronchitis in obstructive airway diseases","volume":"140","author":"Dasgupta","year":"2013","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1186\/1939-4551-7-32_bib0315","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1183\/09031936.00220413","article-title":"The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia","volume":"44","author":"Ortega","year":"2014","journal-title":"Eur Respir J"}],"container-title":["World Allergy Organization Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1939-4551-7-32.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1939-4551-7-32\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455119302649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455119302649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1939-4551-7-32.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T11:49:44Z","timestamp":1556106584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1939455119302649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":63,"alternative-id":["S1939455119302649"],"URL":"https:\/\/doi.org\/10.1186\/1939-4551-7-32","relation":{},"ISSN":["1939-4551"],"issn-type":[{"value":"1939-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2014]]},"article-number":"32"}}